Samsung Biologics Reports Increase in 2023 Net Profit

SEOUL - Samsung Biologics Co. has announced a notable increase in its net profit for the year 2023, reflecting a positive trend in its financial performance. The company, a major player in the biopharmaceutical sector, shared this information in a recent regulatory filing.

According to Yonhap News Agency, the net profit for 2023 reached 857.7 billion won (approximately US$641.5 million), marking a 7.5 percent increase from the previous year. Furthermore, the company's operating income rose to 1.11 trillion won, an increase of 13.2 percent on-year. Additionally, annual sales experienced a significant boost, climbing 23.1 percent to 3.69 trillion won.

scroll to top